BOLD · Boundless Bio, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-23 |
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ) mutation, with proof-of-concept data demonstrating restoration of serum AAT to |
| 2026-05-08 |
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating |
| 2026-04-17 |
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology |
| 2026-03-17 |
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster |
| 2026-03-09 |
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage |
| 2026-03-04 |
Boundless Bio to Participate in the Leerink Global Healthcare Conference
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary |
| 2026-02-05 |
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary |
| 2026-01-20 |
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: |
| 2025-11-24 |
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary |
| 2025-11-05 |
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-23 | Boundless Bio, Inc. Conference Call | Conference |
| 2026-03-11 | Leerink Global Healthcare Conference | Conference |
| 2026-02-12 | Guggenheim Emerging Outlook: Biotech Summit 2026 | Webcast |
| 2025-12-03 | Piper Sandler 37th Annual Healthcare Conference | Conference |